Unlike γ-secretase inhibitors that broadly block all Notch signaling, specific targeting of Dll4 with anti-Dll4 antibodies did not induce overt gastrointestinal toxicity and has thus emerged as an attractive target for anti-angiogenic cancer therapy [30,69]. This evidence concerns the gene DLL4 and cancer.